SG Americas Securities LLC Reduces Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

On February 10, 2025, it was reported that SG Americas Securities LLC has reduced its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 56.4% during the fourth quarter. Following the sale of 4,081 shares, the company now holds 3,161 shares, valued at approximately $175,000 at the end of the latest quarter.

Other institutional investors have also made significant changes to their positions in Tarsus Pharmaceuticals recently. For instance, Jennison Associates LLC increased its stake by 47.2% during the third quarter, acquiring an additional 698,712 shares to reach a total of 2,178,580 shares, worth around $71.65 million. Meanwhile, JPMorgan Chase & Co. dramatically raised its stake by 2,088.8%, adding 420,057 shares for a total of 440,167 shares valued at about $14.48 million. Other firms that have either bought or expanded their holdings include Ally Bridge Group NY LLC, Vestal Point Capital LP, and Ikarian Capital LLC, which all made moves in the third quarter.

Stock Performance of Tarsus Pharmaceuticals

The stock of Tarsus Pharmaceuticals traded at $52.95 on Monday. Its fifty-day simple moving average stands at $52.01, while the 200-day moving average is noted at $40.87. Tarsus has a market capitalization of $2.02 billion, a negative price-to-earnings ratio of -13.90, and a beta of 1.01, indicating a moderate level of volatility. Financial ratios reveal a quick ratio of 5.38 and a current ratio of 5.42, with a debt-to-equity ratio of 0.30. The stock has experienced a 52-week low of $20.08 and a high of $57.28.

Analyst Insights on Tarsus Pharmaceuticals

Several analysts have provided insights and recommendations for Tarsus Pharmaceuticals stock. Barclays increased the price target from $60.00 to $62.00, rating the stock as "overweight." Similarly, Oppenheimer raised its price target from $65.00 to $72.00, while maintaining an "outperform" rating. The Goldman Sachs Group adjusted its target from $36.00 to $41.00, giving it a "neutral" rating. Among the analysts, one has a hold rating, four have issued buy ratings, and one has assigned a strong buy rating. Overall, the consensus rating is "Buy" with a target price averaging $56.00.

Overview of Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. operates as a commercial-stage biopharmaceutical entity focused on the development and commercialization of innovative therapeutic solutions for eye care in the United States. The company’s leading product candidate, XDEMVY, targets the treatment of blepharitis caused by Demodex mite infestation and addresses meibomian gland disease.

Conclusion

With significant shifts among institutional investors and a positive outlook from analysts, Tarsus Pharmaceuticals remains on the radar for stakeholders in the biotech sector. The company's strategies and product pipeline may position it well for continued growth in the competitive healthcare market.

SG, Americas, Tarsus